Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-negative Early Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT05896566
What this trial is testing

A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Who this might be right for
Breast Cancer
ETOP IBCSG Partners Foundation 231
Testing effectiveness (Phase 2)Looking for participantsNCT07287098
What this trial is testing

Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Who this might be right for
Breast Neoplasms
Eli Lilly and Company 600
Testing effectiveness (Phase 2)Study completedNCT03988036
What this trial is testing

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

Who this might be right for
Breast Cancer
Women's Cancer Study Group GmbH 46
Testing effectiveness (Phase 2)UnknownNCT04659499
What this trial is testing

Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer

Who this might be right for
Early Breast Cancer
Peking Union Medical College Hospital 261
Testing effectiveness (Phase 2)UnknownNCT03812393
What this trial is testing

Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast

Who this might be right for
Triple Negative Breast CancerEarly-stage Breast CancerHER2-positive Breast Cancer
West Cancer Center 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT04293393
What this trial is testing

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Who this might be right for
Early Breast Cancer
Spanish Breast Cancer Research Group 200
Not applicableEnrolling By InvitationNCT06791161
What this trial is testing

Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer

Who this might be right for
Breast
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 300
Testing effectiveness (Phase 2)Looking for participantsNCT06452394
What this trial is testing

NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline

Who this might be right for
Breast Cancer
Swiss Cancer Institute 50
Large-scale testing (Phase 3)UnknownNCT01104571
What this trial is testing

Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer

Who this might be right for
Breast Cancer
Institute of Cancer Research, United Kingdom 257
Large-scale testing (Phase 3)Looking for participantsNCT06966700
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Who this might be right for
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC 2,400
Testing effectiveness (Phase 2)Study completedNCT03078751
What this trial is testing

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 54
Testing effectiveness (Phase 2)Looking for participantsNCT07616453
What this trial is testing

Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer

Who this might be right for
HR+/HER2- Early Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 45
Large-scale testing (Phase 3)Looking for participantsNCT06992882
What this trial is testing

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

Who this might be right for
HER2-positive Breast Cancer
Fudan University 2,306
Testing effectiveness (Phase 2)UnknownNCT04848454
What this trial is testing

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

Who this might be right for
HER2-negative Breast CancerNeoadjuvant TherapyPathological Complete Response+3 more
Peking University First Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT06970912
What this trial is testing

CtDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

Who this might be right for
Hormone Receptor-Positive Breast CancerHigh-risk Breast CancerEarly-Stage Breast Cancer+3 more
Peking University People's Hospital 393
Testing effectiveness (Phase 2)Looking for participantsNCT05582499
What this trial is testing

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Who this might be right for
Breast NeoplasmBreast CancerBreast Tumors+7 more
Fudan University 716
Testing effectiveness (Phase 2)Study completedNCT04436744
What this trial is testing

Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

Who this might be right for
Early Breast Cancer
Hoffmann-La Roche 221
Not applicableStudy completedNCT02521363
What this trial is testing

Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 11
Large-scale testing (Phase 3)Looking for participantsNCT04576143
What this trial is testing

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Who this might be right for
HER2-negative Breast CancerNeoadjuvant Chemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 260
Large-scale testing (Phase 3)Active Not RecruitingNCT04055493
What this trial is testing

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Who this might be right for
Breast Cancer Female
Women's Cancer Study Group GmbH 1,684
Next Page